Natural killer (NK) cell engagers binding to NKp46 and BCMA variants with FC-engineering

The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human BCMA and the second ABD binds specifically to human N...

Full description

Saved in:
Bibliographic Details
Main Authors CHIRON, MARIELLE, MASIERO, ALESSANDRO, BENINGA, JOCHEN, LANGE, CHRISTIAN, GAUTHIER, LAURENT, VIRONE-ODDOS, ANGELA, FOCKEN, INGO, GOURDIN, NICOLAS, TILLMANN, BODO, TANG, ALEXANDRE, RAO, SAMBASIVA, ZHOU, YAN-FENG, SEVIGNY, LEILA
Format Patent
LanguageChinese
English
Published 01.04.2024
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human BCMA and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof bind to a human Fc-[gamma] receptor. The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including multiple myeloma (MM).
Bibliography:Application Number: TW202312119749